

WADA Technical Letter – TL08

Document Number:	TL08	Version Number:	5.0
Written by:	WADA Science		
		Approved by:	WADA Executive Committee
Reviewed by:	WADA Laboratory Expert Group		
Date:	21 December 2020	Effective Date:	1 January 2021

USE OF INTERNAL STANDARDS

1.0 Introduction

WADA wishes to draw the attention of the <u>Laboratories</u> to the selection of internal standards for the analysis of anabolic androgenic steroids (AAS) by chromatographic-mass spectrometric techniques.

2.0 Analysis and Reporting Requirements

1. Use of **17α-Methyltestosterone** as Internal Standard

<u>Laboratories</u> shall exercise caution regarding the use of 17α-Methyltestosterone (MT) as an internal standard when analyzing steroids by chromatographic-mass spectrometric techniques. This applies, most importantly, to the <u>Confirmation Procedures</u> (CP).

The MT formation use of as internal standard lead to the of an may 17α-Methyl-5α-androstane-3α,17β-diol and 17α-Methyl-5β-androstane-3α,17β-diol ^[1] when microbial activity is present in urine Samples and, therefore, to the consequent misinterpretation of the result as an Adverse Analytical Finding (AAF). In addition to MT, these artifacts are known Metabolites of various AAS (e.g. Mestanolone, Metandienone, Oxymetholone, Methandriol, and Methyl-1testosterone).

It is highly recommended that <u>CP</u>s for AAS have the following characteristics:

- Avoid metabolic links between the <u>Presumptive Adverse Analytical Finding</u> (PAAF) and the internal standard *e.g.* by using deuterated (²H)- or carbon (¹³C)-labeled internal standards of endogenous steroids instead of MT or any other exogenous AAS;
- Incorporate solid phased extraction (SPE) to clean up the *Sample* prior to the enzymatic hydrolysis, since the direct incubation of already contaminated urine *Samples* may lead to the formation of microbial degradation artifacts and alter the steroid profile.
- 2. Use of Isotopically Labeled Steroids as Internal Standards

It is recommended that ²H- or ¹³C-labeled standards of endogenous steroids are utilized for the <u>Initial</u> <u>Testing Procedure</u> (<u>ITP</u>) applied for the determination of the steroid profile as well as for the <u>CP</u> of steroids in general. However, it may not be optimal to employ isotopically labeled standards of **Testosterone** and **Epitestosterone** for all *Samples* due to:

i. The potential contribution of the fraction of non-labeled compound when these endogenous steroids are present at low concentrations; and



WADA Technical Letter – TL08

Document Number:	TL08	Version Number:	5.0
Written by:	WADA Science		
		Approved by:	WADA Executive Committee
Reviewed by:	WADA Laboratory Expert Group		
Date:	21 December 2020	Effective Date:	1 January 2021

- ii. The potential interference caused by ${}^{2}H_{3}$ or ${}^{13}C_{3}$ -E with the detection of the M-15 ion of bistrimethylsilylated 17 α -methylandrostanediols (*m/z* 435).
- 3. Additional recommendation for qualitative CP

Whenever the internal standard to be used in a qualitative <u>CP</u> has to be identical to the one used in the relevant <u>ITP</u>, and where decomposition or metabolism of the internal standard could potentially contribute to a false positive result for the <u>Non-Threshold Substance</u> subject to the <u>CP</u>, <u>Laboratories</u> should consider the concomitant analysis of one extra <u>Aliquot</u> without the addition of any internal standard.

3.0 References

[1] Schweizer G., Baume N., and Saugy M. Degradation of methyltestosterone in urine samples. *Drug Test Anal.* **6**(11-12): 1170-3, 2014.